Skip to main content
SpringerLink
Log in

Vemurafenib-related tumour lysis syndrome: WHO reports

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Grundmark B. Vemurafenib and Tumour lysis syndrome. WHO Pharmaceuticals Newsletter : 25-7, No. 4, Aug 2015. Available from: URL: http://www.who.int/medicines/publications/Pharm_Newsletter4_2015.pdf

  2. Roche. Response from Roche (re: Vemurafenib and Tumour lysis syndrome). WHO Pharmaceuticals Newsletter : 27-8, No. 4, Aug 2015. Available from: URL: http://www.who.int/medicines/publications/Pharm_Newsletter4_2015.pdf

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vemurafenib-related tumour lysis syndrome: WHO reports. Reactions Weekly 1568, 6 (2015). https://doi.org/10.1007/s40278-015-5064-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-015-5064-y

Search

Navigation